Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819687 | 1.00 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956709 | 1.00 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956714 | 1.00 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL30956705 | 0.87 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL20819557 | 0.87 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL29356232 | 0.87 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL249507 | 0.87 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819586 | 0.86 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819585 | 0.86 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819580 | 0.86 | ADRB1 (0.69) | ADRB1ADRB2HIF1ACYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0224001-B1 | ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1991-03-20 | — | — | EP | claimed |
| US-4863959-A | Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1989-09-05 | — | — | US | claimed |
| EP-0224001-A1 | Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | claimed |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| CN-111148731-B | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| US-20200268688-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-08-27 | — | — | US | disclosed |
| EP-3681857-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| CN-111148731-A | Fluorophenyl β -hydroxyethylamine and use thereof in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019053426-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053426-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-0224001-B1 | ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4863959-A | Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0224001-A1 | Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268688-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | ADRB1 87/4885ADRB2 151/4885HIF1A 402/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | ADRB1 87/4885ADRB2 151/4885HIF1A 402/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | ADRB1 87/4885ADRB2 151/4885HIF1A 402/4885 |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | ADRB1 87/4885ADRB2 151/4885HIF1A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.